




**Figure S1. Expression of tagged host glycolytic enzymes in uninfected cells.** Confocal micrographs of HeLa cells expressing 3xFLAG-tagged Aldolase A (AldoA), Pyruvate Kinase (PKM2), or Lactate Dehydrogenase (LDHA) (green). The cells were fixed at 42 h post transfection and stained with anti-FLAG antibodies. N: Nucleus. Scale bar: 10 $\mu$ m.



**Figure S2. Inclusions are negative for Aldolase A at 8 h post infection.** Confocal micrographs of HeLa cells expressing 3xFLAG-tagged Aldolase A (AldoA), infected for 8 h with the mCherry CtL2 strain (red), and immunostained with anti-FLAG antibodies (green). The merge is shown on the right. Scale bar: 10 $\mu$ m.




**Figure S3. GFP-tagged purine biosynthesis enzymes do not localize at the inclusion membrane.** Confocal micrographs of HeLa cells expressing GFP-tagged Glycinamide ribonucleotide transformylase (GART) or Phosphoribosylaminoimidazole carboxylase (PAICS) (green) and infected for 24 h with the mCherry CtL2 strain (red). The merge is shown on the right. Scale bar: 10 $\mu$ m.




**Figure S4. Validation of Cytochalasin D, Brefeldin A, and Nocodazole drug treatments.**

(A) Confocal micrographs of HeLa cells infected with the mCherry CtL2 strain (red) and fixed at 24 h post infection following the absence (Mock, left panel) or presence of 1  $\mu$ M Cytochalasin D at 23.5 h post infection (Treated, right panel) and immunostained with Phalloidin (green). (B) Confocal micrographs of HeLa cells infected with the mCherry CtL2 strain (red) and fixed at 24 h post infection following the absence (Mock, left panel) or presence of 33  $\mu$ M Nocodazole at 23.5 h post infection (Treated, right panel) and immunostained with anti- $\alpha$ -tubulin antibodies (green). (C) Confocal micrographs of HeLa cells expressing YFP-Golgi (green), infected with the mCherry CtL2 strain (red), and fixed at 24 h post infection following the absence (Mock, left panel) or presence of 1  $\mu$ g/mL Brefeldin A at 6 h post infection (Treated, right panel). Scale bar: 20  $\mu$ m.



**Figure S5. Host actin does not affect localization of Aldolase A at the inclusion membrane.**

(A) Confocal micrographs of HeLa cells expressing wild-type 3xFLAG-AldoA (WT, top panels), or point mutants no longer able to bind actin 3xFLAG-R42A AldoA (R42A, middle panels) and 3xFLAG-R148A AldoA (R148A, bottom panels) (green), infected with the mCherry CtL2 strain (red) and fixed at 24 h post infection. (B) Confocal micrographs of HeLa cells expressing 3xFLAG-AldoA (green) and infected with wild-type *C. trachomatis* (WT, left panel) or an *inaC* mutant strain (*inaC::aadA*, right panel) that were fixed at 24 h post infection. The asterisk indicates the inclusion. N: Nucleus. Scale bar: 10 $\mu$ m.



**Figure S6. Validation of group II intron insertion in the *C. trachomatis inaC::aadA* mutant.**

(A) PCR analysis of the *inaC::aadA* mutant. The *inaC* ORF was amplified from genomic DNA extracted from WT *C. trachomatis* (WT) or the *inaC::aadA* mutant and the corresponding PCR products were resolved on a 1% DNA agarose gel stained with ethidium bromide. Lane 1: molecular weight marker; lane 2: WT; lane 3: *inaC::aadA* mutant. The marker sizes are listed in kilo base pairs to the left. (B) The site of insertion of the group II intron was determined by Sanger sequencing. A translation of the resulting InaC truncated peptide is presented. The asterisk denotes the early stop codon introduced by insertion of the group II intron (black: InaC, red: group II intron).

**Table S1: Primers used in this study**

<b>Primer Name</b>	<b>Primer Sequence</b>
AldoA Fwd BamHI	GGAGGATCCATGCCCTACCAATATCCAGCACTG
AldoA Rev XhoI	CTCCTCGAGTTAATAGGCGTGGTTAGAGAC
PKM2 Fwd BamHI	GGAGGATCCATGTCTGAAGCCCCATAGTGAAGC
PKM2 Rev XhoI	CTCCTCGAGTCACGGCACAGGAACAACACG
LDHA Fwd EcoRI	GAAGAATTCTATGGCAACTCTAAAGGATCAG
LDHA Rev XhoI	CTCCTCGAGTTAAAATTGCAGCTCCTTTTG
HAldoA 5 KpnI	GGTGGTACCATGTACCCTTACGATGTACCGGATTACGCAATGCCCTACCAATATCC
AldoA 3 NotI	GCGGCGGCCGCTTAATAGGCGTGGTTAGAGACG
R42A AldoA Fwd	GAGCATTGCCAAGGCACTGCAGTCCATTGG
R42A AldoA Rev	CCAATGGACTGCAGTGCCTTGGCAATGCTC
R148 AldoA Fwd	CTTCGCCAAGTGGGCATGTGTGCTGAAG
R148 AldoA Rev	CTTCAGCACACATGCCCACTTGGCGAAG
CTL0184 129 130 IBS1/2	AAAAAAGCTTATAATTATCCTTATCATGCATCGCAGTGCGCCAGATAGGGTG
CTL0184 129 130 EBS1/delta	CAGATTGTACAAATGTGGTGATAACAGATAAGTCATCGCAGGTAACCTTTCTTTGT
CTL0184 129 130 EBS2	TGAACGCAAGTTTCTAATTTTCGATTCATGATCGATAGAGGAAAGTGTCT
CTL0184 Up	GCAGAAATAGGTCTGAGGCTG
CTL0184 Dwn	CAACGAATTAGACATTCGTC

**Table S2: Primers and probes used for quantitative PCR analysis**

<b>Gene</b>	<b>Probe</b>	<b>Primer</b>	<b>Sequence</b>
16S rRNA	#105	Ct 16s Fwd	gccgctaataccgaatgtg
		Ct 16s Rev	aaggtcctaagatccccttctt
<i>omcA</i>	#33	CTL0703 Fwd	cggtggtgcaactcttgta
		CTL0703 Rev	tcagcatcttggtgcgtatc
<i>pgi</i>	#69	CTL0633 Fwd	gctgctgcatagcaagac
		CTL0633 Rev	atacagaaactctgcaagacgaag
<i>dhnA</i>	#24	CTL0467 Fwd	ttcagtcaagttgaagatgccta
		CTL0467 Rev	agtaaatcgttgctccgacag
<i>pykF</i>	#159	CTL0586 Fwd	gataggccctgcaacgaata
		CTL0586 Rev	cattcatccctgcatcgag